Loading
Latest filing published 30 Nov 2023 for SAB Biotherapeutics, Inc., €4,101.
No signal scores available.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Only one filing by Michael King is known so far (30 November 2023): an open-market purchase, €4,101, in SAB Biotherapeutics, Inc. That is too little to draw conclusions. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
1 of 1 declaration